ASCO 2022 Conference Coverage

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Breast
Lung
GI
GU
Skin
GYN
Head & Neck
Leukemia
Lymphoma
Myeloma
MDS and MPN
Sarcoma

Playback speed

June 14, 2022

Feat. S. Dawood

Feat. W. Mchayleh

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

V. Bandovkina

ASCO 2022 Conference Coverage

J. Bussel, C. Mcguinn

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

C. Lee Batlevi

ASCO 2022 Conference Coverage

C. Lee Batlevi

ASCO 2022 Conference Coverage

Login

Login

Join VuMedi

ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLARGO Trial: Polatuzumab Vedotin + Rituximab, Gemcitabine, and Oxaliplatin in R/R DLBCL

Supporting Patients With Breast Cancer in the Clinic: Setting the Pa…

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

2022 ASCO Annual Meeting "The Effects of AVM0703 Mobilization of End…

Lecture Summary - ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequen…

ASCO 2022 on the Phase 2 KEYNOTE-C11 Study: Sequential Pembro & Chem…

Lecture Summary - ASCO 2022 on the Phase III frontMIND Study: Tafasi…

ASCO 2022 on the Phase III frontMIND Study: Tafasitamab + Lenalidomi…

ASCO 2022 on the Analysis of Peripheral Neuropathy in 1L DLBCL Using…

ASCO 2022 ADCs and CARs: Racing to Cure Aggresive Lymphoma

ASCO 2022 on the Predictive Value of TGFβ1/TGFBR2 Ratio for Evaluati…

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophi…

Lecture Summary - ASCO 2022 Treatment Patterns and Real-World Effect…

ASCO 2022 Treatment Patterns and Real-World Effectiveness of Rituxim…

ASCO 2022 Three-Year Follow-Up of Outcomes With KTE-X19 in R/R Mantl…

Lecture Summary - ASCO 2022 Three-Year Follow-Up of Outcomes With KT…

ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma: Re…

Lecture Summary - ASCO 2022 Brexucabtagene Autoleucel for R/R Mantle…

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLA…

ASCO 2022 Correlates of Common Concerns in Older Cancer Survivors of…

Lecture Summary - ASCO 2022 Real World Experience of Combined Treatm…

ASCO 2022 Real World Experience of Combined Treatment With Romidepsi…

Lecture Summary - ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as …

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

Lecture Summary - ASCO 2022 on Clinical & PROs in a Phase III, Rando…

ASCO 2022 on Clinical & PROs in a Phase III, Randomized, Open-Label …

ASCO 2022 on CRC-403: A Phase 1/2 Study of bbT369, A Dual Targeting …

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomiz…

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Stud…

ASCO 2022 PACIFIC Trial Updates: Response Kinetics, Safety & Efficac…